Purpose
Type 2 diabetes (T2D) imparts an increased risk of adverse health outcomes in patients unable to achieve glycemic control. Patient education and individualization of treatment are important for effective management of T2D. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are a class of injectable glucose-lowering agents that lower A1C with added benefits of weight loss and improved cardiovascular risk markers. This review discusses the role of GLP-1RAs currently approved in the United States (exenatide, liraglutide, albiglutide, dulaglutide) for T2D management and characterizes the efficacy and safety profiles of individual GLP-1RAs.
Conclusions
GLP-1RAs are recommended as a preferred add-on agent to existing metformin monotherapy, as first-line therapy if metformin is contraindicated or poorly tolerated, and for use in combination with other oral glucoselowering agents or basal insulin. Shorter-acting GLP-1RAs (exenatide and liraglutide) offer improved coverage of postprandial hyperglycemia, while longeracting GLP-1RA formulations (exenatide extendedrelease, dulaglutide, and albiglutide) further improve fasting plasma glucose, which can result in additional A1C lowering. Reductions in body weight and blood pressure appear similar among individual agents, and small increases in heart rate are of unknown clinical relevance. Gastrointestinal adverse events abate over time with continued treatment and are less frequent with longer-acting GLP-1RAs. Hypoglycemia incidence is low but increased when GLP-1RAs are used with insulin secretagogues or insulin. GLP-1RAs target multiple pathophysiologic mechanisms in patients with T2D and improve glycemic control, although there are some differences within this drug class that may be relevant in clinical practice. Therefore, selection of the most appropriate treatment for individual patients is important. G lucagon-like peptide-1 receptor agonists (GLP-1RAs) are injectable glucoselowering medications that have been approved as an adjunct to diet and exercise for the treatment of adults with type 2 diabetes (T2D). [1] [2] [3] [4] [5] GLP-1RAs offer effective glycemic control with the added benefits of weight loss, low risk of hypoglycemia, and positive effects on cardiovascular risk factors. [6] [7] [8] Five GLP-1RA products are currently available in the United States: exenatide, exenatide extended-release, liraglutide, albiglutide, and dulaglutide. Exenatide extended-release, albiglutide, and dulaglutide are once-weekly longer-acting GLP-1RAs, while exenatide and liraglutide are shorter acting and administered twice daily and once daily, respectively. 6 All GLP-1RAs share the same basic mechanism of action, but the various agents have heterogeneous clinical efficacy and adverse event profiles that may enable physicians to match patients to the compound most likely to benefit them. [8] [9] [10] GLP-1RAs are increasingly being prescribed in the primary care setting and represent an important treatment option for patients with T2D 8, 10, 11 ; thus, this article provides an overview of the GLP-1RA class of compounds to aid in their incorporation into clinical practice.
Mechanism of Action
An understanding of the mechanism of action of glucose-lowering therapies is important because it enables providers to select add-on therapies that complement the medications that their patients are already using. Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) are incretins, peptide hormones secreted from the gastrointestinal tract in response to nutrient ingestion that act on structurally distinct receptors. 12 Glucose-dependent insulinotropic polypeptide is not a therapeutic target for GLP-1RAs and is therefore not discussed in this article. During a meal, plasma levels of the incretin hormones rise rapidly and then return to baseline levels in the fasting state. 13, 14 GLP-1 binds to GLP-1 receptors expressed in the pancreas and a variety of other tissues, including the cardiovascular and central nervous systems, 13 exerting a number of direct pharmacologic actions ( Figure 1 ). 9,10 GLP-1 also exerts indirect pharmacologic effects via activation of signaling pathways in the brain. 13, 15 Treatment of T2D with GLP-1RAs occurs via both glucose-dependent and extraglycemic mechanisms of action.
Incretin receptor activation on pancreatic β cells leads to glucose-dependent insulin secretion and inhibition of glucagon secretion. 13 Because insulin secretion is glucose dependent, the risk of treatment-related hypoglycemia is minimized. 10 Excessive glucagon release from pancreatic α cells is inhibited with GLP-1 receptor stimulation in conditions of hyperglycemia, but counterregulatory glucagon release and activity during hypoglycemia is not inhibited. 16 Intestinal GLP-1 receptor stimulation exerts further extraglycemic glucoregulatory actions through slowed gastric emptying and reduced intestinal motility, which contribute to reduced postprandial glucose (PPG) excursions, increased satiety, and weight loss. 8, 10, 12 Patients with T2D typically have impaired incretin-mediated increases in insulin secretion due to decreased GLP-1 secretion (or GLP-1 resistance). [17] [18] [19] The GLP-1RA class of medications mimics the actions of the endogenous GLP-1 hormone and can help to offset this impairment.
The History of GLP-1RAs
In the early 1990s, a team of investigators isolated a peptide-exendin-4-from the saliva of the Gila monster (Heloderma suspectum) that has 53% amino acid homology with native GLP-1 and exhibited GLP-1-like activity. 20 Endogenous GLP-1 undergoes rapid breakdown and inactivation by dipeptidyl peptidase-4 (DPP-4), 21 which was initially a limiting factor to its therapeutic potential. In contrast, exendin-4 is resistant to degradation by DPP-4 due to a different amino acid at the proteolytic cleavage site, thereby opening the possibility for an injectable agent providing sustained GLP-1 receptor agonism. Subsequent pharmaceutical development led to approval of the first GLP-1RA-exenatide-in the United States in 2005. 9 Exenatide is a synthetic version of exendin-4 that has >50% amino acid homology with native GLP-1, as well as affinity for the GLP-1 receptor and receptor activation equivalent to that of native GLP-1. 22 The exenatide molecule is the most extensively studied of the GLP-1RAs, with >7 years of continuous clinical follow-up data. Commercial development of exenatide was followed by liraglutide in 2010 and then the longer-acting GLP-1RAs, including exenatide extended-release in 2012 and albiglutide and dulaglutide in 2014. [23] [24] [25] [26] [27] These GLP-1RAs have varying structural similarity to native human GLP-1 and exhibit resistance to enzymatic degradation by DPP-4, resulting in a longer half-life than that of native GLP-1. 9 Long-acting GLP-1RA formulations have been achieved through microsphere (exenatide extended-release) or fusion protein technology (albiglutide and dulaglutide). [8] [9] [10] Differences in molecular structure and pharmacokinetic profiles among GLP-1RAs (Table 1 ) may have implications for the efficacy and tolerability of these compounds. [8] [9] [10] 
GLP-1RAs and Their Place in the Treatment Paradigm
According to guidelines from the American Diabetes Association and European Association for the Study of Diabetes published in 2015, the standard-of-care treatment for patients newly diagnosed with T2D is metformin in addition to lifestyle changes. 6, 28 GLP-1RAs and other glucose-lowering medications (sulfonylureas, thiazolidinediones [TZDs], DPP-4 inhibitors, sodium glucose cotransporter-2 [SGLT2] inhibitors, and basal insulin) are recommended in combination with metformin as second-line therapy after failure to achieve A1C goal on metformin alone and according to patient factors and tolerability. For patients with high A1C (≥9% [75 mmol/ mol]) at diagnosis, initial metformin-based combination therapy may allow patients to achieve A1C targets more quickly than a trial of monotherapy followed by combination therapy. 6, 28 GLP-1RAs can also be used as an alternative to first-line metformin therapy for patients with T2D who are unable to take metformin. 6 Moreover, the 2015 American Diabetes Association/European Association for Table 1 Chemical Properties and Pharmacokinetic Profiles of GLP-1RAs [1] [2] [3] [4] [5] 9, 76 the Study of Diabetes guidelines also recommend the addition of a GLP-1RA or mealtime insulin for patients taking basal insulin with ≥1 oral agents whose diabetes remains uncontrolled, with GLP-1RAs being a more attractive option for obese patients or those who may not be able to handle the complexities of a multidose insulin regimen. 6 The American Association of Clinical Endocrinologists' treatment algorithm published in 2015 recommends metformin, GLP-1RAs, SGLT2 inhibitors, DPP-4 inhibitors, or alpha-glucosidase inhibitors as initial choices for monotherapy for patients with A1C <7.5% (<58.5 mmol/ mol) at diagnosis. 29, 30 For patients with initial A1C ≥7.5% (≥58.5 mmol/mol), dual combination therapy with metformin is recommended. GLP-1RAs are recommended as the first-line add-on therapy to metformin in this patient population, followed by SGLT2 inhibitors, DPP-4 inhibitors, TZDs, basal insulin, colesevelam, bromocriptine, alpha-glucosidase inhibitors, or sulfonylureas. For patients with initial A1C >9.0% (>74.9 mmol/mol) without symptoms of hyperglycemia, dual or triple combination therapy with metformin or another first-line agent (without insulin) is recommended, while for patients with A1C >9.0% (>74.9 mmol/mol) and hyperglycemia symptoms, insulin therapy with or without metformin or other oral glucose-lowering agents is recommended.
GLP-1RAs are appealing because of their high glucose-lowering effect, potential for weight loss, and low risk of hypoglycemia. 6, 29, [31] [32] [33] Because of relative cost compared with metformin and the subcutaneous route of administration, GLP-1RAs are generally not considered a first-line monotherapy. 24 Additionally, because of the uncertain relevance of preclinical findings of thyroid C-cell tumors in rodents to humans, practitioners are cautioned against first-line use in respective drug labeling. 1, 2, 4, 5 The GLP-1RAs can be used as monotherapy or in various combinations with metformin, sulfonylureas, TZDs, insulin glargine (exenatide twice daily, liraglutide, or albiglutide), or prandial insulin (dulaglutide only), 1,3-6,29 but GLP-1RAs are not recommended to be used in combination with DPP-4 inhibitors. 6 Because GLP-1RAs provide high levels of GLP-1 agonism, the addition of a DPP-4 inhibitor-which acts by suppressing the breakdown of endogenous GLP-1 by DPP-4-is considered unlikely to provide additional benefit. Furthermore, there are limited data to support the GLP-1RA + DPP-4 inhibitor treatment approach or, at this time, the use of SGLT2 inhibitors in conjunction with GLP-1RAs. 6 While major treatment guidelines recommend a sequential and stepwise approach to the treatment of most treatment-naïve patients with T2D, 6,28 a recent proof-ofconcept study may advocate for a more aggressive approach. In the open-label EDICT study (Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes), 249 treatment-naïve patients with T2D were randomized to receive triple combination therapy with metformin, pioglitazone, and exenatide twice daily or a sequential approach of metformin, followed by glimepiride and then basal insulin as necessary to achieve A1C <6.5% (<47.5 mmol/mol). 34 At 2 years, A1C was reduced from a baseline value of 8.6% (70.5 mmol/mol) in both treatment groups to 5.95% (41.5 mmol/mol) with triple combination therapy and 6.50% (47.5 mmol/mol) for conventional treatment (treatment difference = 0.55% [6.0 mmol/mol]; P < .0001). A greater proportion of patients maintained the A1C goal of <6.5% (47.5 mmol/mol) on triple combination therapy versus conventional treatment at or after 6 months (13 vs 40 patients above goal; P < .0001) with less frequent hypoglycemia (0.31 vs 2.2 events/patient/ year; P < .0001). However, note that the differences in strategy for treatment and medications used in the 2 study arms are of scientific interest but also a limitation of the study and that the results are not necessarily generalizable to other treatments.
GLP-1RAs in Combination With Insulin
For patients with T2D not achieving an agreed A1C target despite intensive noninsulin therapy, basal insulin can be considered a treatment option. 6, 29, 30, 35 Basal insulin can also be considered a treatment option for treatmentnaïve patients with A1C >9.0% (>74.9 mmol/mol) and hyperglycemia symptoms. 29, 30 For patients with uncontrolled diabetes on basal insulin with ≥1 oral agents, including metformin, the addition of a GLP-1RA or prandial insulin is recommended. 6 Patients who administer basal or prandial insulin are subject to risks of hypoglycemia and weight gain, necessitating the self-monitoring of blood glucose, selftitration of insulin doses, and potentially other daily measures (eg, carbohydrate counting) to maintain glucose near target levels. 6, 28 Thus, a GLP-1RA may be a better option than insulin in more obese individuals due to the potential for weight loss. A GLP-1RA may also be a better therapeutic choice in individuals who may not be able to manage the complexities of a multidose insulin regimen. 6 Recent studies suggest that the combination of a short-acting or weekly GLP-1RA with basal insulin has at least equal efficacy when compared with the addition of prandial insulin to basal insulin; it is also associated with weight loss and a low risk of hypoglycemia. 6 To limit the risk of hypoglycemia, it is recommended that patients with a stable basal insulin dose and A1C ≤8.0% (≤63.9 mmol/mol) have their basal insulin dose empirically decreased by 20% when initiating a GLP-1RA. 36, 37 For patients with A1C >8.0% (>63.9 mmol/mol) or those who may be far from achieving planned glycemic goals, a GLP-1RA may be initiated without empiric basal insulin dose reduction. 36, 37 Clinical Effects of GLP-1RAs Data from phase 3 clinical studies demonstrate that GLP-1RAs provide glycemic control with the added benefit of weight loss and a low risk of hypoglycemia.
Exenatide
Exenatide, administered twice daily, was found to reduce A1C, fasting plasma glucose (FPG), and body weight in the three 30-week AMIGO trials (AC2993 Diabetes Management for Improving Glucose Outcomes) [38] [39] [40] and in the 2 additional studies that investigated twice-daily exenatide versus an insulin comparator. 41, 42 Hypoglycemia incidence was greater in studies that allowed background sulfonylurea use as compared with studies where patients were taking only background metformin (19%-36% vs 5%). [38] [39] [40] Exenatide Extended-Release
The DURATION clinical trial program (Diabetes Therapy Utilization: Researching Changes in A1C, Weight and Other Factors Through Intervention With Exenatide Once Weekly) demonstrated that exenatide extended-release as monotherapy and as part of combination therapy over treatment durations of 24 to 30 weeks was effective in improving glycemic control and reducing body weight and produced a modest improvement in systolic blood pressure (SBP). [43] [44] [45] [46] [47] [48] [49] [50] Hypoglycemia incidence was similar to that with liraglutide, metformin, pioglitazone, and sitagliptin in head-to-head studies and was lower compared with insulin glargine. Long-term treatment with exenatide extended-release was also effective, with significant reductions from baseline in A1C, FPG, weight, total cholesterol, low-density lipoprotein cholesterol, triglycerides, and diastolic blood pressure over 5 years (all P < .05 vs baseline). 51 Minor hypoglycemia was more common among exenatide-treated patients taking a concomitant sulfonylurea than patients who were nonsulfonylurea users.
Liraglutide
The effects of liraglutide have been investigated in the 6 LEAD studies (Liraglutide Effect and Action in Diabetes) of patients with T2D as part of monotherapy or combination therapy with oral glucose-lowering agents. [52] [53] [54] [55] [56] [57] In these studies, maximally titrated liraglutide (1.8 mg once daily) over 26 to 52 weeks resulted in reductions from baseline in A1C, FPG, weight, and SBP. Hypoglycemia incidence was higher versus comparator rosiglitazone treatment and lower as compared with glimepiride, insulin glargine, and exenatide BID. Liraglutide (1.8 mg once daily) monotherapy over 2 years was associated with significant reductions in A1C, FPG, weight, and waist circumference (all P < .05 vs glimepiride comparator). 58 
Dulaglutide
Dulaglutide has been studied in the AWARD clinical trial program (Assessment of Weekly Administration of LY2189265 [dulaglutide]). 5, [59] [60] [61] [62] These studies showed that treatment with dulaglutide (1.5 mg once weekly) with background glucose-lowering therapy over 26 to 52 weeks resulted in reductions from baseline in A1C, FPG, and weight, and changes in SBP ranging from a small increase (0.11 mm Hg) to reductions up to 3.4 mm Hg. Hypoglycemia incidence was greater versus comparator liraglutide and sitagliptin, similar to metformin, and less frequent than exenatide BID treatment.
Albiglutide
Albiglutide has been studied in the HARMONY clinical trial program. 4, [63] [64] [65] [66] Four clinical trials of 26 to 104 weeks have been published, across which albiglutide (30 to 50 mg once weekly) was associated with reductions from baseline in A1C and FPG. 63, 64, 66, 67 Changes from baseline in weight ranged from +0.3 to -1.2 kg. Hypoglycemia incidence was higher with albiglutide versus comparator sitagliptin and lower versus comparator glimepiride, liraglutide, and insulin lispro.
Pharmacodynamic Differences Among the GLP-1RAs Glycemic Control
The sustained activity of the longer-acting GLP-1RAs dulaglutide and exenatide extended-release produces better fasting glucose control while maintaining some postprandial activity, leading to better overall A1C reduction (Figure 2A ), 8 whereas shorter-acting GLP-1RAs are associated with delayed gastric emptying and strong PPG effects. [8] [9] [10] In the 2 studies of 24 to 30 weeks comparing exenatide extended-release with exenatide 10 µg twice daily, exenatide extended-release had better efficacy with regard to A1C and FPG reductions, 44, 49 but reductions from baseline in 2-hour PPG excursions were significantly greater with twice-daily exenatide (P = .01). 49 Dulaglutide 1.5 mg once weekly resulted in significantly greater reductions in A1C (P < .001), FPG (P < .001), and the mean of all PPG values (P = .047) when compared with exenatide 10 µg twice daily through 26 weeks of treatment. 62 Similar to the longer-acting GLP-1RAs dulaglutide and exenatide extended-release, liraglutide was shown to be superior to short-acting exenatide with respect to A1C reduction, although exenatide had greater effects on PPG. In studies of liraglutide (1.8 mg once daily) versus exenatide extended-release and albiglutide (30 mg once weekly), the longer-acting GLP-1RAs had slightly reduced efficacy in terms of improvements in A1C and FPG when compared with liraglutide (significant vs exenatide extended-release for A1C and FPG and significant vs albiglutide for FPG only) and similar efficacy for dulaglutide versus liraglutide. 45, 59, 64 Changes in PPG were similar for the comparison of liraglutide (1.8 mg once daily) versus dulaglutide (1.5 mg once weekly; P = .26). 59 Changes in PPG were not available for comparisons with exenatide extended-release and albiglutide. 45, 64 No a priori basis exists to explain the observed differences in efficacy of long-acting agents versus liraglutide, and it has been suggested that differences in dose estimations are 1 possible reason for apparent differences. 23, 32 Blood Pressure and Heart Rate Short-and long-acting GLP-1RAs lower blood pressure and increase heart rate, but the clinical relevance of this heart rate increase is unknown. A meta-analysis of 32 clinical trials (25 exenatide trials, 7 liraglutide trials; search date July 2012) showed that, as compared with placebo and active control, exenatide and liraglutide demonstrated, respectively, overall decreases in SBP of 1.79 and 2.39 mm Hg, decreases in diastolic blood pressure of 0.54 and 0.50 mm Hg, and increases in heart rate of 1.86 and 1.9 beats per minute (bpm). 68 Lund et al proposed that there may be a trend toward an increase in heart rate with the longer-acting GLP-1RAs versus the shorter-acting GLP-1RAs 9 ; however, in head-to-head studies comparing shorter-and longer-acting GLP-1RAs, increases in heart rate were numerically greater with liraglutide (1.8 mg once daily) versus dulaglutide (1.5 mg once weekly) for 26 weeks (+3.12 vs +2.37 bpm; P = .25) and albiglutide (50 mg once weekly) for 32 weeks (+3 vs +1 bpm). 59, 64 Comparisons of liraglutide versus exenatide extended-release were not available. Upcoming cardiovascular outcomes studies may help determine if there are any potential safety concerns related to increases in heart rate with GLP-1RA treatment.
Although GLP-1RAs are associated with improvements in cardiovascular disease risk factors ( 
Body Weight
Decreases in body weight have been observed with all GLP-1RA treatments (Figure 2B) . At maximal doses, weight loss was significantly greater with liraglutide 1.8 mg once daily versus exenatide extended-release 2 mg once weekly (-3.6 vs -2.7 kg, respectively; P < .05), dulaglutide 1.5 mg once weekly (-3.6 vs -2.9 kg; P < .05), and albiglutide 50 mg once weekly (-2.2 vs -0.6 kg; P < .05), 45, 59, 64 while similar reductions in weight from baseline were observed for liraglutide 1.8 mg once daily versus exenatide 10 µg twice daily (-3.2 vs -2.9 kg) and for exenatide 10 µg twice daily versus dulaglutide 1.5 mg once weekly (-1.1 vs -1.3 kg). 52, 62 Central effects seem to mediate the body weight-reducing effects of the GLP-1RAs. 8, 9 However, because albiglutide and dulaglutide are larger fusion proteins, they may not cross the blood-brain barrier to the same extent as exenatide and liraglutide, and this may result in smaller effects on body weight. 8, 9 Decreases in body weight with GLP-1RA treatment may also partially explain reductions in blood pressure that have been observed. 69 
Safety Profile of GLP-1RAs
GLP-1RAs are generally well tolerated. 70 The most common side effects are gastrointestinal, most frequently mild and transient nausea. 70, 71 The incidence of nausea seems to be highest with the short-acting agents ( Table 2) , possibly because of fluctuations in plasma GLP-1 levels. 8, 9 Nausea incidence has been observed to decrease over time with continued dosing for both short-and longacting GLP-1RAs. 45, 72 Recently approved dulaglutide has been associated with gastrointestinal adverse events, 7% and 11% of which were graded as severe by investigators in clinical trials with dulaglutide 0.75 and 1.5 mg, respectively. 5 Injection-site reactions are common with long-acting injectable agents, [73] [74] [75] and with exenatide once weekly there is a risk of nodule formation from the poly(D,Llactic-co-glycolic acid; PLG) microspheres used in the long-acting formulation. 76 PLG microspheres have been used for extended-release delivery systems and as sutures, bone plates, and implants for surgery. These nodules are a localized "foreign body reaction" 42 Exenatide 5 → 10 μg BID (n = 282) MET + SU 57 a 17 Insulin glargine 10 U/d initially with self-titration to FG <100 mg/dL (<5.6 mmol/L; n = 267) 9 4 Diamant et al (2014; 30 wk) 41 Exenatide 5 → 10 μg BID (n = 315) Insulin glargine with titration to achieve 4.0-5.5 mmol/L without hypoglycemia 32 12 Insulin lispro TID with titration to achieve FG of 5.6-6.0 mmol/L (n = 312) 2 1
Exenatide extended-release Drucker et al (2008; 30 wk) 49 Exenatide 2 mg QW (n = 148) MET, SU, TZD, or any 2 26 11 Exenatide 5 → 10 μg BID (n = 147) 35 19 Bergenstal et al (2010; 26 wk) 43 Exenatide 2 56 Insulin glargine (n = 234) MET + SU (continued) inflammatory response to the PLG microspheres, are approximately 0.5 to 0.75 cm in diameter, are usually painless, and generally resolve in 3 to 6 weeks without medical intervention. 76 In a pooled analysis of exenatide extended-release clinical trials, injection-site nodules were reported as adverse events in 7% of patients, with an exposure-adjusted incidence rate of 0.16% per patientyear. 77 Injection-site pruritus can also occur with GLP-1RA treatment 77 but has been shown to decrease over time in long-term extension studies. 51, 78 The risks of pancreatitis and pancreatic cancer have been investigated for GLP-1RAs. [79] [80] [81] Recent parallel assessments of the pancreatic safety of incretin-based therapies were conducted by the US Food and Drug Administration and European Medicines Agency using data from clinical trials, epidemiologic studies, and toxicology studies. 82 Based on the available evidence, it was concluded that proposed causal association between treatment with GLP-1RAs and DPP-4 inhibitors and the development of pancreatic adverse events is not supported. 82 Animal studies have shown that long-term activation of parafollicular thyroid C cells by GLP-1RAs is associated with increased calcitonin secretion, C-cell proliferation, and tumor formation. 83 However, GLP-1 receptors do not appear to be commonly present in human thyroid tissue, although approximately one-third of medullary thyroid carcinomas may express GLP-1 receptors. 84, 85 Cases of medullary thyroid carcinoma have been reported for patients treated with liraglutide during the postmarketing period, although data are insufficient to establish or exclude a causal relationship. 1 Thus, out of caution, the longer-acting GLP-1RAs are contraindicated for patients with a personal or family history of medullary thyroid carcinoma and for patients with multiple endocrine neoplasia syndrome type 2. 1,2,4,5
Patient Education
Patient education is a key component of the management of T2D, particularly when injectable therapies are to be used. 86 Negative perceptions of insulin therapyincluding concerns regarding pain, discomfort, weight gain, and hypoglycemia-may be carried over by patients to GLP-1RAs and other injectable therapies, thereby acting as barriers to their uptake. 86 In a French cohort of the multinational Diabetes, Attitudes, Wishes and Needs survey, only 57% to 61% of treatment-naïve patients with T2D expressed willingness to take insulin or GLP-1RAs if prescribed. 87 Physicians may preferentially prescribe oral therapies because (1) they believe that patients will have poor adherence to injectable therapy and (2) they have insufficient resources to educate patients on its use. [88] [89] [90] Patient education on the need for and value of injectable therapy, correct injection techniques, and management of expectations has been shown to reduce fear of injections and support initiation and adherence of injectable therapy. 91 As T2D is a chronic disease, patient education should be ongoing and continuous and should adapt to patients' evolving health and needs.
The use of needles that take into consideration patient comfort or the prescribing of pen devices that facilitate ease of dosing is recommended with education to improve adherence. 86 Available GLP-1RAs can be delivered through pen devices that vary in design and ease-of-use features [1] [2] [3] [4] [5] ; exenatide extended-release is also available through needle and syringe delivery by single-dose tray. 2 The pen device for liraglutide requires that the exact dose be dialed in before use, with dose splitting across pens if the cartridge becomes empty. 1 Pen devices for exenatide twice-daily administration are multiuse pens but deliver only 1 dose, 3 while exenatide extended-release, albiglutide, and dulaglutide are administered through single-dose, single-use pens that are disposed immediately after use. 2, 4, 5 All pen devices require a series of steps to be performed before use. Instructions for use are enclosed with the pen device to guide patients through this process. Diabetes educators should review the instructions with patients in the office setting before first use and at subsequent followup visits to ensure that patients are using the pen device correctly. Key counseling points for the use of pen devices include the following: correct procedure steps to deliver a dose, refrigeration of the pen prior to first use (exenatide and liraglutide multiuse pens can be kept at room temperature after first use), 1 priming dose at the beginning of each new pen for exenatide and liraglutide, hand washing and inspection of the medication for cloudiness or particulate matter before use, and holding the pen and dose button firmly in place for the required time upon injection (the authors usually recommend 10 seconds) after dose delivery to ensure that the total dose is delivered.
Conclusions
Patient education and the selection of appropriate and effective treatment based on individual patients' characteristics and therapeutic needs are important components of the management of T2D. GLP-1RAs target the multifaceted pathophysiology of T2D and complement the mechanisms of action of other commonly used glucoselowering medications. They offer the opportunity for improvements in glucose control with a minimal increase in the risk of hypoglycemia and with the added benefits of weight loss and improvements in other cardiovascular risk factors. Long-acting GLP-1RAs may be favored for additional A1C lowering, improved gastrointestinal tolerability, and improved patient convenience due to less frequent dosing, but short-acting compounds seem preferable for patients with predominant postprandial hyperglycemia. More head-to-head studies of GLP-1RAs are needed to better elucidate differences in the clinical efficacy and safety profiles of individual agents.
